Novavax Covid-19 vaccine elicits immune response in early trial

New York, Aug 5 (IANS): A Covid-19 vaccine developed by US-based Novavax elicited robust antibody responses and appeared to be safe in a Phase-I human trial, the company has said.

No serious adverse events were reported and safety follow-up continues, Novavax said on Tuesday, while releasing the results of the study about its Covid-19 vaccine, NVX-CoV2373.

The trial evaluated two doses of the vaccine across two dose levels -- 5 and 25 microgram -- in 131 healthy adults ages 18-59 years.

The trial was supported by funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and was conducted at two sites in Australia.

"The Phase 1 data demonstrate that NVX-CoV2373 with our Matrix-M adjuvant is a well-tolerated COVID-19 vaccine with a robust immunogenicity profile," Gregory Glenn, President, Research and Development at Novavax, said in a statement.

"Using a stringent wild-type virus assay performed by investigators at the University of Maryland School of Medicine, NVX-CoV2373 elicited neutralising antibody titers greater than those observed in a pool of COVID-19 patients with clinically significant disease."

NVX-CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes Covid-19 disease.

It was created using Novavax' recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and contains Novavax' patented saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

The company said the data of the Phase-1 trial have been submitted for peer-review to a scientific journal and to an online preprint server at

Novavax has become the third US company to release Phase-1 data of Covid-19 vaccines after Moderna and Pfizer.

Novavax was awarded $1.6 billion by the US government as part of Operation Warp Speed (OWS), a program to deliver millions of doses of a safe, effective vaccine for Covid-19 to the US population.

The funding is being used by Novavax to complete late-stage clinical development, including a pivotal Phase 3 clinical trial, establish large-scale manufacturing, and deliver 100 million doses of NVX-CoV2373 beginning as early as late 2020, the company said.


Top Stories


Title : Novavax Covid-19 vaccine elicits immune response in early trial


You have 2000 characters left.


Please write your correct name and email address. Kindly do not post any personal, abusive, defamatory, infringing, obscene, indecent, discriminatory or unlawful or similar comments. will not be responsible for any defamatory message posted under this article.

Please note that sending false messages to insult, defame, intimidate, mislead or deceive people or to intentionally cause public disorder is punishable under law. It is obligatory on Daijiworld to provide the IP address and other details of senders of such comments, to the authority concerned upon request.

Hence, sending offensive comments using daijiworld will be purely at your own risk, and in no way will be held responsible.

Security Validation

Enter the characters in the image